Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

2.9K
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis.

ESMO open·2026
Same author

Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.

ESMO gastrointestinal oncology·2026
Same author

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study.

ESMO gastrointestinal oncology·2026
Same author

Ga-68-Edotreotide PET/CT SSTR Total Tumor Volume as a Predictor of Outcome in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors.

Cancer control : journal of the Moffitt Cancer Center·2026
Same author

Energy Spectrum of Ultrahigh-Energy Cosmic Rays across Declinations -90° to +44.8° as Measured at the Pierre Auger Observatory.

Physical review letters·2026
Same author

Perampanel effects on seizures and sleep quality in people with epilepsy: A prospective multicenter study.

Epilepsy & behavior : E&B·2025

Related Experiment Video

Updated: Mar 15, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.4K

Therapeutic Strategies in HCC: Radiation Modalities.

R Gallicchio1, A Nardelli2, P Mainenti2

  • 1Nuclear Medicine Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Via P. Pio 1, 85028 Rionero in Vulture, Italy.

Biomed Research International
|August 27, 2016
PubMed
Summary

For advanced hepatocellular carcinoma (HCC) patients ineligible for surgery, radiation-based therapies like transarterial radioisotope delivery offer promising treatment options. These methods focus on targeted tumor reduction and improved survival with minimal toxicity.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Related Experiment Videos

Last Updated: Mar 15, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.4K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Area of Science:

  • Hepatobiliary Medicine
  • Radiation Oncology
  • Interventional Radiology

Background:

  • Advanced hepatocellular carcinoma (HCC) often precludes radical treatment options.
  • Transarterial chemoembolization (TACE) and external radiation therapy (RTx) have shown limited efficacy or tolerance issues in HCC.
  • Novel radiation-based therapies are needed for unresectable HCC.

Purpose of the Study:

  • To review the role of radiation-based therapies in managing advanced HCC.
  • To highlight transarterial metabolic radiotherapy (TAMR) as a promising treatment modality.
  • To discuss the potential of novel radioisotopes and combined treatment approaches.

Main Methods:

  • Review of transarterial metabolic radiotherapy (TAMR) using (131)I Lipiodol or (90)Y microspheres.
  • Discussion of external radiation therapy (RTx) advancements, including 3D conformal RTx.
  • Exploration of combined therapeutic strategies, including chemotherapy.

Main Results:

  • TAMR demonstrates efficacy in tumor shrinkage and survival for advanced HCC.
  • TAMR offers targeted local radiation delivery, preserving healthy liver tissue and minimizing systemic exposure.
  • External RTx shows encouraging results with improved liver tolerance.
  • TAMR exhibits adequate therapeutic responses with limited toxicities compared to TACE.

Conclusions:

  • Radiation-based therapies, particularly TAMR, represent a significant advancement for unresectable HCC.
  • Technological innovations in RTx and radioisotopes offer new avenues for HCC treatment.
  • Combining radiation therapies with other modalities like chemotherapy holds potential for improved patient outcomes.